- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00976638
Clinical Trial to Reduce Antibiotic Resistance in European Intensive Cares (MOSAR-ICU)
Mastering Hospital Antibiotic Resistance, a Cluster Randomized Intervention Study in Intensive Care Units Throughout Europe (Work Package 3)
Colonization of patients with Antimicrobial Resistant Bacteria (AMRB) like Methicillin Resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE) and Extended-Spectrum Beta-Lactamases (ESBL) enterobacteriaceae leads to infections; and ultimately to adverse outcomes (eg prolonged hospital stay, death). This is an urgent problem in Europe, especially in Intensive Care Units (ICUs).
In this trial, colonization of patients with these AMRB will be assessed in the baseline period (6m). In phase 2 the effect of a Hygiene Improvement Program, including Chlorhexidine body washings and a Hand Hygiene training program, will be assessed (6m). In phase 3 units will be randomized to either Active Surveillance with Chromagar based tests or a Molecular based tests.
Study Hypothesis: the abovementioned interventions will reduce ICU-acquired colonization rates with MRSA, VRE and ESBL.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A cluster-randomized trial with a stepped wedge design will be conducted in adult ICU's throughout Europe
The MOSAR-ICU trial is motivated by three primary considerations:
- Advances in behavioral sciences and research about (hand) hygiene compliance have allowed a better understanding of barriers to increase compliance with (hand) hygiene practices within healthcare institutions;
- Recent investigations have identified new rapid tests, both chromogenic media and molecular based tests, which may help identifying previously unknown carriage of AMRB at the time of admission; and
- Currently practiced procedures, such as regular surveillance of all patients and daily cleansing of ICU patients with Chlorhexidine, have not been evaluated properly for their effectiveness.
In conclusion, evidence base derived recommendations from prospective studies regarding the costeffectiveness of different control strategies are lacking.
This study assess the impact of the three interventions on ICU acquired colonisation rates for AMRB(MRSA,VRE and ESBL).
Study design: Multi-center, cluster-randomised clinical trial.
Study population: Adult patients admitted to the ICU.
Intervention: The first phase of the study will be a 6-month baseline period to determine acquisition rates of AMRB during current standard practice in the individual participating centers (including currently performed surveillance strategies). The second phase will consist of a Hygiene Improvement Program to improve standard precautions and hand hygiene; and daily washing of all ICU patients with Chlorhexidine gluconate (HIP; 6 months). In both periods Contact Precautions (contact isolation) will be implemented for carriers of AMRB, as identified upon clinical cultures and following current practice of individual wards. In the third phase of the study (12 months) units will be randomized, and all interventions of phase 2 will be continued in all units. Half of the units will implement surveillance (admission and twice weekly cultures) of all admitted patients for carriage of MRSA and VRE using chromogenic agar. The other half will add molecular based rapid testing of ALL admission cultures for MRSA and VRE in addition to twice weekly screening of all patients with Chromagar based tests for MRSA, VRE and ESBL.
Main study endpoints: ICU-acquired colonization rates with MRSA, VRE and ESBL.
Primary Objective: To evaluate the impact of enhanced standard barrier precautions and rapid screening with targeted isolation of patients carrying AMRB on transmission of AMRB.
Secondary Objectives:
- Evaluate the impact of interventions on ICU-acquired bacteremia rates with MRSA, VRE or ESBL.
- Evaluate the impact of the HIP intervention on frequency and quality of hand hygiene, the application of standard precautions and the use of contact precautions during patient care.
- Evaluate the effect of the three strategies on other patient outcomes, including length of stay and in hospital mortality.
- Evaluate the overall antibiotic use and effectiveness of empirical treatment of ICU-acquired bacteremia.
- Evaluate the effect of the three strategies on the incidence density of new acquisitions with MRSA, VRE and ESBL individually.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Creteil, France, 94000
- Hopital Henri Mondor
-
Garches, France, F-92380
- Raymond Poincaré Hospital
-
Paris, France, 75674
- Hopital Paris Saint Joseph
-
-
-
-
-
Athens, Greece, 12462
- University General Hospital Attikon
-
Athens, Greece, 11527
- Laikon General Hospital
-
-
-
-
-
Rome, Italy, 00152
- San Camillo Forlanini Hospital
-
-
-
-
-
Riga, Latvia, LV-1008
- Paul Stradins University Hospital
-
-
-
-
-
Luxembourg, Luxembourg, L-1210
- Centre Hospitalier de Luxembourg
-
-
-
-
-
Porto, Portugal, 4260-363
- Hospital Geral de Sto Antonio
-
Vila Real, Portugal, 5000-508
- Tras-os-Montes e Alto Douro
-
-
-
-
-
Golnik, Slovenia, 4204
- University Clinic of Respiratory and Allergic Diseases
-
Ljubljana, Slovenia, SI 1000
- University Medical Center Ljubljana
-
-
-
-
-
Barcelona, Spain, 8025
- Hospital Clinic Y Provencal
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- colonization with either MRSA, VRE or ESBL is endemic
- at least one dedicated infection control physician
- ability to obtain, store and analyze surveillance cultures
- at least 8 ICU beds; all of which have possibility for mechanical ventilation
- ability to collect the data required for analysis
- written approval of the institution's IRB
- signed protocol signature page
Exclusion Criteria:
- burn units
- cardiothoracic units
- pediatric and neonatal ICUs
- ICU is currently using rapid diagnostic testing in their screening program for AMRB
- ICU is planning to enroll subjects in studies testing investigational agents for the purpose of eradicating or preventing colonization with MRSA, VRE or ESBL or devices or practice management strategies that have colonization and/or infection with AMRB as an outcome
- using SOD/ SDD or any topical antimicrobial therapy
- using chlorhexidine body washings
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Chromogenic Arm
Active surveillance of colonization with MRSA or VRE by chromogenic agar with isolation of positive patients.
|
All admitted patients are screened on admission for MRSA and VRE by chromogenic agar and isolated when positive
Other Names:
|
Active Comparator: Molecular Arm
Active surveillance of colonization with MRSA and VRE by PCR; and of ESBL by chromogenic agar with isolation of positive patients
|
All patients are screened for MRSA and VRE by PCR; and for ESBL by chromogenic agar on admission.
Positive patients are isolated
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Colonization with MRSA, VRE and ESBL
Time Frame: On admission
|
By taking surveillance swabs from nose, perineum and wounds (if present) on admission we will assess whether patients are colonized with MRSA, VRE and ESBL at the moment of ICU admission.
Swabs will be processed on chromogenic agars.
|
On admission
|
Colonization with MRSA, VRE and ESBL
Time Frame: During ICU stay
|
By taking surveillance swabs twice weekly from nose, perineum and wounds (if present) we will assess whether patients become colonized with MRSA, VRE and ESBL during ICU stay. Swabs will be processed on chromogenic agars. Note: for patients admitted for longer than 21 days, surveillance is reduced to once weekly. |
During ICU stay
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence density of new acquisitions with MRSA, VRE and ESBL individually.
Time Frame: Acquired during ICU stay (median LOS 14 days)
|
In phase 2, we implement a hygiene improvement program. We will assess if this program reduces the number of patients acquiring colonization with MRSA, VRE and ESBL. We will measure colonization as stated in the primary outcome measure. In phase 3, we will implement direct feedback of screening results, and isolation of colonized patients. Swabs will be processed either by chromogenic agar (a) or molecular tests (b). Thus, the effect of these interventions on incidence density of new acquisitions of MRSA, VRE or ESBL will be assessed. |
Acquired during ICU stay (median LOS 14 days)
|
ICU-acquired bacteremia rates with MRSA,VRE or ESBL.
Time Frame: Acquired during ICU stay (median LOS 14 days)
|
We will collect data on all bacteremias occuring during ICU stay, after completion of the trial.
We include all bacteremias with s aureus (MSSA and MRSA), e faecium/ e faecalis ("S" and "R") and enterobacteriaceae ("S" and "R").
Data will be collected from the microbiology labs.
|
Acquired during ICU stay (median LOS 14 days)
|
28 day-mortality
Time Frame: 28 days
|
We will collect length of stay, and disposition at d28 as well as disposition at discharge from the ICU.
Data will be collected in the online CRF.
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marc Bonten, Prof, MD, UMC Utrecht
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LSHP-CT-2007-037941
- WP3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hospital Acquired Infections
-
Indiana UniversityWithdrawnHospital Acquired MRSA | Community Acquired MRSAUnited States
-
National University of SingaporeSaglik Bilimleri UniversitesiRecruitingHospital-acquired InfectionsCambodia
-
Hong Kong University of Science and TechnologyQueen Elizabeth Hospital, Hong Kong; Kowloon Hospital, Hong Kong; Innovation...CompletedHospital Acquired InfectionsHong Kong
-
Assaf-Harofeh Medical CenterGama Healthcare Ltd.CompletedHospital Acquired InfectionIsrael
-
Peking University Third HospitalCompletedHospital Acquired InfectionChina
-
Shanghai Zhongshan HospitalNot yet recruitingAnalgesia | Hospital-acquired Infections
-
National Institute of Allergy and Infectious Diseases...Completed
-
University Hospital, Basel, SwitzerlandRecruiting
-
Shanghai Zhongshan HospitalRecruitingSurgery | Intensive Care Unit | Hospital-Acquired Infection | ChlorhexidineChina
-
Bactiguard ABCompletedHospital Acquired Infections | Endotracheal Intubation During SurgerySweden
Clinical Trials on Chromogenic surveillance
-
The Second Affiliated Hospital of Dalian Medical...Fudan University; West China Hospital; Shengjing Hospital; The First Affiliated... and other collaboratorsRecruiting
-
Memorial Sloan Kettering Cancer CenterRecruitingSquamous Cell CarcinomaUnited States
-
Royal Marsden NHS Foundation TrustPelican Cancer FoundationNot yet recruiting
-
University of AlbertaCompleted
-
University of SydneyMelanoma and Skin Cancer Trials LimitedCompleted
-
Intermountain Health Care, Inc.UnknownDeep Vein Thrombosis | Venous Thromboembolism | Trauma, MultipleUnited States
-
The University of Texas Health Science Center at...CompletedBladder CancerUnited States
-
University Health Network, TorontoActive, not recruiting
-
Fox Chase Cancer CenterRecruitingCancer | SurgeryUnited States
-
Kaiser PermanentePatient-Centered Outcomes Research Institute; University of California, Davis; University of California, San FranciscoActive, not recruitingLung Neoplasms | Solitary Pulmonary Nodule | Carcinoma, Non-small-cell Lung | Coin Lesion, PulmonaryUnited States